BRAF and thyroid gland papillary carcinoma: In 2014, The Cancer Genome Atlas (TCGA) reported that classification of adult papillary thyroid cancer (PTC) into molecular subtypes on the basis of an messenger RNA expression signature, RAS-like and BRAF-like, more accurately reflected cellular signaling, cellular differentiation, and clinical behavior when compared with histology alone.1 This observation has led to discussions as to whether identification of oncogenic alterations could be used to stratify therapy, including the extent of surgery, lobectomy versus total thyroidectomy, as well as central compartment lymph node dissection.2,3